- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07915765
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence (ENDETECT)
This non-interventional study aims to assess the impact of an endometriosis diagnosis obtained through a salivary test (Ziwig Endotest®) on pain-related cognitions, quality of life, mood, and treatment adherence, comparingthese outcomes with those of individuals who underwent the same salivary test but received a negative result and were therefore not diagnosed with endometriosis.
Participation in this study will contribute to advancing research in the field of endometriosis diagnosis and multidisciplinary management by expanding current knowledge of diagnostic protocols and their impact on pain, quality of life, treatment adherence, and potential psychiatric comorbidities. The investigators hope to enhance understanding of endometriosis and pelvic pain symptomatology in order to develop new therapeutic strategies, including psychological interventions or integrated psychological care, that better address the needs and specific characteristics of patients whether or not they receive a diagnosis of endometriosis.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Celine CLAIRET-LESPINASSE
- Telefonnummer: +33 3204441145
- E-post: celine.clairet@chu-lille.fr
Studera Kontakt Backup
- Namn: DRS. Promotion
- Telefonnummer: +33 3204441145
- E-post: drs.promotion@chu-lille.fr
Studieorter
-
-
-
Lille, Frankrike
- CHU de Lille
-
Kontakt:
- Celine CLAIRET-LESPINASSE
- Telefonnummer: +33320444145
- E-post: celine.clairet@chu-lille.fr
-
Kontakt:
- Chrydtele RUBOD DIT GUILLET, Pr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients referred for suspected endometriosis, with negative imaging findings and for whom an endotest has been indicated.
Beskrivning
Inclusion Criteria:
- Patients eligible for an endotest as part of the innovation package at Jeanne de Flandre Hospital
- Patients between 18 to 43 years old
- Understand and can communicate in French
- Having received medical images that do not allow the diagnosis of endometriosis
- Presenting with symptoms suggestive of endometriosis
- Giving oral non-opposition to participe in the study
- Beneficiary of health insurance coverage
- Having normal visual and auditory acuity or corrected to normal levels
Exclusion Criteria:
- Minors, adults under guardianship, under judicial protection, and persons deprived of liberty
- Refusal to participate after receiving clear and fair information about the study
- Sensory, visual or auditory inability to participate in the study
- Personal history of neurological disorders or current neurological disorder
- Consumtion of toxic substances other than tobacco and alcohol.
- Personal history of psychiatric disorders or current psychiatric disorders other than anxiety, depressive, or trauma- and stress-related disorders
- Use of psychotropic medications
- Pregnant or breastfeeding women
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: CASE_ONLY
- Tidsperspektiv: PROSPECTIVE
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Changes in pain catastrophizing 1 month after being informed of the results of the saliva test among patients diagnosed with endometriosis and among patients not diagnosed with endometriosis.
Tidsram: 1 month + 3 weeks
|
Change in the Pain Catastrophizing Scale score between baseline and 1 month after the announcement of the salivary test results. Use : Questionnaire Pain Catastrophizing scale-13 items divided into three dimensions: "rumination," "magnification," and "helplessness"-scored on a scale of 0 to 4-maximum total score of 52 points. |
1 month + 3 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Changes 1 month after the consultation during which the results of the salivary test for pain catastrophizing were announced, based on the diagnosis of endometriosis.
Tidsram: 6 months + 3 weeks
|
Change from baseline to 1 month after the announcement of the salivary test results in the Pain Catastrophizing Scale score. Use : Questionnaire Pain Catastrophizing scale-13 items divided into three dimensions: "rumination," "magnification," and "helplessness"-scored on a scale of 0 to 4-maximum total score of 52 points. |
6 months + 3 weeks
|
|
Changes at 1 month and 6 months after the consultation during which the saliva test results were announced, based on whether endometriosis was diagnosed: • Quality of life • Anxiety and depressive symptoms • Treatment adherence
Tidsram: 6 months + 3 weeks
|
Change from baseline to 1 month after the results were announced, and from baseline to 6 months after the results were announced. Use:
|
6 months + 3 weeks
|
|
Changes at 6 months following the consultation during which the results of the salivary test for pain catastrophizing were reported, based on the diagnosis of endometriosis.
Tidsram: 6 months + 3 weeks
|
To compare the change in pain catastrophizing at 6 months following the consultation disclosing the salivary test results, between patients diagnosed with endometriosis and those not diagnosed with endometriosis. Use : Questionnaire Pain Catastrophizing scale-13 items divided into three dimensions: "rumination," "magnification," and "helplessness"-scored on a scale of 0 to 4-maximum total score of 52 points. |
6 months + 3 weeks
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Mentala störningar
- Patologiska processer
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Beteendesymtom
- Genitala sjukdomar, kvinnor
- Patologiska tillstånd, tecken och symtom
- Beteende
- Ångeststörningar
- Depression
- Sjukdom
- Endometrios
Andra studie-ID-nummer
- 2025_0266
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .